DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 2, 2022, covering events occurring on February 28, 2022, and March 1, 2022. DarioHealth Corp. (DRIO), a Delaware corporation listed on the Nasdaq Capital Market, reported the entry into a material definitive agreement for a registered direct offering and a new strategic partnership.
Key Financial Metrics and Capital Structure
The filing details a capital raise rather than operational financial results. Key metrics include:
- Gross Proceeds: Approximately $40 million before deducting offering expenses.
- Securities Issued: 4,674,454 shares of Common Stock and pre-funded warrants to purchase 667,559 shares.
- Offering Price: $7.49 per share for Common Stock; $7.4899 per Pre-Funded Warrant.
- Liquidity Impact: The offering is expected to close on or about March 3, 2022, subject to customary conditions.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes and Strategic Developments
Two primary material events were reported:
- Registered Direct Offering: The Company entered into a Securities Purchase Agreement with institutional investors. Investors agreed to a three-day lock-up period. Pre-Funded Warrants are exercisable immediately but subject to beneficial ownership limitations (4.99% or 9.99% at purchaser election, with a 19.99% hard cap without shareholder approval).
- Strategic Partnership: On March 1, 2022, the Company announced it was selected by Sanofi (Nasdaq: SNY) as its preferred partner for digital health solutions.
Outlook, Risks, and Contingencies
The offering is contingent upon the satisfaction of customary closing conditions. The Pre-Funded Warrants include specific limitations on exercise to prevent beneficial ownership exceeding 19.99% of outstanding shares without shareholder approval. The filing incorporates the full text of the Securities Purchase Agreement and Pre-Funded Warrants by reference for complete terms.
Investor Verification Checklist
- Verify the final closing date of the offering and the net proceeds after deducting offering expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Assess the commercial terms and revenue potential of the new partnership with Sanofi.
- Monitor the dilution impact of the 4,674,454 new shares and 667,559 pre-funded warrants on existing shareholders.